M-A de estudos randomizados | Colchicina e riscos de doença cardíaca coronariana.

Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials – Frontiers in Cardiovascular Medicine

Conteúdos relacionados:

M-A: Colchicine after percutaneous coronary intervention significantly reduces the risk of major adverse cardiovascular events in patients with symptomatic coronary artery disease.

Expert Analysis | Colchicine in acute coronary syndrome: when to commence?

M-A: Colchicine in patients with coronary artery disease – “colchicine reduces the risk of myocardial infarction and stroke, but has a higher rate of gastrointestinal upset with no influence on all‐cause mortality”.

Review: Colchicine and the heart.

M-A: Colchicine administration for percutaneous coronary intervention

M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease

Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease

Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease

#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease

#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome

#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

#AHA19 – [Abstract Only] Practice Changing? – Randomized Trial: Low-Dose Colchicine Improves Outcomes after Myocardial Infarction

Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome